Warner-Lambert v Actavis ‘disappointing’ for innovators: lawyers

The UK Supreme Court’s decision in Warner-Lambert v Actavis is disappointing for pharmaceutical innovators, and enforcing second medical use patents may now be more challenging, lawyers have told LSIPR.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

UK Supreme Court issues Warner-Lambert v Actavis ruling

14 November 2018 The UK Supreme Court today dismissed Warner-Lambert’s appeal in its pregabalin patent dispute with Actavis, while clarifying the role of plausibility in the sufficiency of patent applications.

Big Pharma

Warner-Lambert v Actavis: a summary from the UK Supreme Court hearing

21 February 2018 Infringement and plausibility were the biggest issues on the battleground in the UK Supreme Court’s hearing in a case dealing with second medical use patents, as Claire Phipps-Jones, Katie Cambrook and Rachel Mumby of Bristows report.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Warner-Lambert v Actavis ‘disappointing’ for innovators: lawyers

More on this story

Editor's picks

Editor's picks

More features